Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUAL study of bevacizumab versus ranibizumab for exudative age-related macular degeneration
NL-OMON28472Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in age-related macular degeneration (AMD) comparing Bevacizumab arm with Ranibizumab arm (2 arms). Primary endpoint: Change in best-corrected visual acuity. Planned start Jul 2008; status: not yet recruiting.
02
Drugs
bevacizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON28472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28472.